Aurobindo Pharma has got the final approval from the US health regulator for generic version of an intravenous antidote to a pain killer drug overdose.

It said in a BSE filing that “The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetylcysteine Injection, 6g/30 mL (200 mg/mL) single-dose vials.”

The product is likely to be launched in the first quarter of the next fiscal.

Read EquityPandit’s Nifty Pharma Outlook for this week